BST:NBYB

Stock Analysis Report

Executive Summary

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally.


Snowflake Analysis

Weak fundamentals or lack of information.


Similar Companies

Share Price & News

How has Northwest Biotherapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NBYB's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-5.9%

NBYB

11.2%

DE Biotechs

7.3%

DE Market


1 Year Return

-43.3%

NBYB

-5.1%

DE Biotechs

-17.7%

DE Market

Return vs Industry: NBYB underperformed the German Biotechs industry which returned -5.1% over the past year.

Return vs Market: NBYB underperformed the German Market which returned -17.5% over the past year.


Shareholder returns

NBYBIndustryMarket
7 Day-5.9%11.2%7.3%
30 Day-19.6%-5.3%-17.9%
90 Day-29.0%-21.9%-25.8%
1 Year-43.3%-43.3%-4.9%-5.1%-15.1%-17.7%
3 Year-42.0%-42.0%17.7%16.5%-18.7%-25.6%
5 Yearn/a-5.1%-7.5%-17.7%-29.0%

Price Volatility Vs. Market

How volatile is Northwest Biotherapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Northwest Biotherapeutics undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Northwest Biotherapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Northwest Biotherapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of NBYB’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Northwest Biotherapeutics regulatory filings.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is Northwest Biotherapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

58.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Northwest Biotherapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Northwest Biotherapeutics performed over the past 5 years?

25.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NBYB is currently unprofitable.

Growing Profit Margin: NBYB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NBYB is unprofitable, but has reduced losses over the past 5 years at a rate of 25.2% per year.

Accelerating Growth: Unable to compare NBYB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NBYB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: NBYB's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Northwest Biotherapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: NBYB has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: NBYB has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: NBYB has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: NBYB's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: NBYB has a high level of physical assets or inventory.

Debt Coverage by Assets: NBYB has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NBYB has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: NBYB has less than a year of cash runway if free cash flow continues to grow at historical rates of 13.7% each year.


Next Steps

Dividend

What is Northwest Biotherapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NBYB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate NBYB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NBYB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NBYB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NBYB's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

8.8yrs

Average management tenure


CEO

Linda Powers (63yo)

8.75s

Tenure

US$7,200,000

Compensation

Ms. Linda F. Powers, J.D., has been the Chief Executive Officer and President of Northwest Biotherapeutics, Inc. since June 8, 2011 and also served as its Chief Financial Officer and Accounting Officer. Ms ...


CEO Compensation Analysis

Compensation vs Market: Linda's total compensation ($USD7.20M) is above average for companies of similar size in the German market ($USD432.27K).

Compensation vs Earnings: Linda's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Linda Powers
Chairperson8.75yrsUS$7.20m4.46% $4.1m
Alton Boynton
Founder22.17yrsUS$1.85m0.0019% $1.7k
Marnix Bosch
Chief Technical Officer13.17yrsUS$635.00k0.0015% $1.4k
Leslie Goldman
Senior VP & General Counselno dataUS$4.56m0.026% $24.1k
Jean Davis
CFO, Chief Accounting Officer & Interim CIO0.25yrno datano data
David Innes
Vice President of Investor Relations1yrno datano data
Anthony Maida
Senior Vice President of Clinical Research6.17yrsUS$300.00kno data
Pankaj Shah
Financial Controller12.08yrsno datano data

8.8yrs

Average Tenure

65yo

Average Age

Experienced Management: NBYB's management team is seasoned and experienced (8.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Linda Powers
Chairperson8.75yrsUS$7.20m4.46% $4.1m
Alton Boynton
Founder22.17yrsUS$1.85m0.0019% $1.7k
Jerome Jasinowski
Lead Independent Directorno dataUS$987.00k0.29% $264.4k
Henry Brem
Member of Clinical Advisory Board14.5yrsno datano data
Tom Mikkelsen
Member of Clinical Advisory Board14.5yrsno datano data
Linda Liau
Chairman of Clinical Advisory Board14.5yrsno datano data
Steven Brem
Member of Clinical Advisory Board14.5yrsno datano data
Darell Bigner
Member of Clinical Advisory Board14.5yrsno datano data
Navid Malik
Independent Director7.92yrsUS$1.70m0.0015% $1.4k
J. Black
Independent Director4.17yrsUS$443.00kno data

14.5yrs

Average Tenure

67.5yo

Average Age

Experienced Board: NBYB's board of directors are seasoned and experienced ( 14.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.2%.


Top Shareholders

Company Information

Northwest Biotherapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Northwest Biotherapeutics, Inc.
  • Ticker: NBYB
  • Exchange: BST
  • Founded: 1996
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$102.301m
  • Listing Market Cap: US$92.265m
  • Shares outstanding: 660.01m
  • Website: https://www.nwbio.com

Number of Employees


Location

  • Northwest Biotherapeutics, Inc.
  • 4800 Montgomery Lane
  • Suite 800
  • Bethesda
  • Maryland
  • 20814
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NWBOOTCPK (Pink Sheets LLC)YesCommon StockUSUSDDec 2001
NBYBBST (Boerse-Stuttgart)YesCommon StockDEEURDec 2001

Biography

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. It is developing DCVax-L, a product in Phase III clinical trials to treat Glioblastome multiforme, a brain cancer; and DCVax-Direct, a product in Phase I/II clinical trials to treat various types of inoperable solid tumor cancers. The company was founded in 1996 and is headquartered in Bethesda, Maryland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/29 23:10
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.